These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33035337)

  • 1. DockCoV2: a drug database against SARS-CoV-2.
    Chen TF; Chang YC; Hsiao Y; Lee KH; Hsiao YC; Lin YH; Tu YE; Huang HC; Chen CY; Juan HF
    Nucleic Acids Res; 2021 Jan; 49(D1):D1152-D1159. PubMed ID: 33035337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
    Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
    Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
    Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C
    Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.
    Raj K; Kaur K; Gupta GD; Singh S
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jul; 394(7):1383-1402. PubMed ID: 33961065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.
    Ghanbari R; Teimoori A; Sadeghi A; Mohamadkhani A; Rezasoltani S; Asadi E; Jouyban A; Sumner SC
    Future Microbiol; 2020 Dec; 15():1747-1758. PubMed ID: 33404263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
    Yapasert R; Khaw-On P; Banjerdpongchai R
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
    Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
    Sternberg A; McKee DL; Naujokat C
    Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Malekmohammad K; Rafieian-Kopaei M
    Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights of key enzymes into therapeutic intervention against SARS-CoV-2.
    Shahid M; Shahzad-Ul-Hussan S
    J Struct Biol; 2021 Mar; 213(1):107690. PubMed ID: 33383190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.
    Murugan NA; Kumar S; Jeyakanthan J; Srivastava V
    Sci Rep; 2020 Nov; 10(1):19125. PubMed ID: 33154404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.
    Wang R; Stephen P; Tao Y; Zhang W; Lin SX
    Biomed Pharmacother; 2021 May; 137():111232. PubMed ID: 33486202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
    Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
    Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.